Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.47 +3.3%	$8.92	$2.99 ▼ $10.87	$1.54B	1.8	1.57 million shs	2.89 million shs
IOVA Iovance Biotherapeutics	$2.04 +1.0%	$2.49	$1.64 ▼ $12.51	$674.55M	0.86	8.94 million shs	8.36 million shs
NVAX Novavax	$6.30 -2.9%	$6.71	$5.01 ▼ $17.81	$1.05B	2.8	6.48 million shs	6.46 million shs
OYST Oyster Point Pharma	$11.17	$11.15	$3.46 ▼ $19.00	$299.85M	1.31	212,171 shs	330 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-1.46%	-3.06%	+12.04%	+34.13%	+222.93%
IOVA Iovance Biotherapeutics	-2.88%	-15.13%	+21.69%	-43.26%	-75.00%
NVAX Novavax	-7.68%	-9.86%	-3.57%	-17.95%	-53.81%
OYST Oyster Point Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.8277 of 5 stars	1.4	1.0	0.0	4.2	2.9	2.5	0.6
IOVA Iovance Biotherapeutics	4.5978 of 5 stars	4.3	1.0	0.0	4.2	1.7	4.2	1.3
NVAX Novavax	4.5569 of 5 stars	3.1	2.0	0.0	4.7	2.6	0.8	3.1
OYST Oyster Point Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	0.97% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	551.96% Upside
NVAX Novavax	2.29	Hold	$17.00	169.84% Upside
OYST Oyster Point Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OYST, IOVA, ADPT, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.89	N/A	N/A	$1.37 per share	7.64
IOVA Iovance Biotherapeutics	$164.07M	4.15	N/A	N/A	$2.33 per share	0.88
NVAX Novavax	$682.16M	1.50	N/A	N/A	($3.89) per share	-1.62
OYST Oyster Point Pharma	$24.54M	12.22	N/A	N/A	$3.80 per share	2.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.38	78.75	0.07	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
OYST Oyster Point Pharma	-$100.66M	-$6.65	N/A	N/A	N/A	-901.99%	-490.33%	-108.29%	N/A

Latest OYST, IOVA, ADPT, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
OYST Oyster Point Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
NVAX Novavax	N/A	2.06	2.03
OYST Oyster Point Pharma	8.49	3.35	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
IOVA Iovance Biotherapeutics	77.03%
NVAX Novavax	53.04%
OYST Oyster Point Pharma	96.70%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
IOVA Iovance Biotherapeutics	10.30%
NVAX Novavax	1.00%
OYST Oyster Point Pharma	17.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
OYST Oyster Point Pharma	303	26.84 million	22.04 million	Not Optionable

OYST, IOVA, ADPT, and NVAX Headlines

Recent News About These Companies

Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation

April 1, 2025 | finance.yahoo.com

Billion-dollar real estate bet could spark a biotech revival

March 21, 2025 | bizjournals.com

Vibrant Wintertime Flower At Oyster Point: Photo

February 20, 2025 | msn.com

Next phase of Kilroy's big Oyster Point project sees interest beyond biotech

February 11, 2025 | bizjournals.com

The Oyster Point Gallery presents "The Cut-Outs" by Gary Steven Groves

January 14, 2025 | newjerseystage.com

Ted Danson, Kristen Bell and D’Arcy Carden Reunite at “A Man on the Inside ”Premiere 4 Years After “The Good Place ”(Exclusive)

November 12, 2024 | msn.com

Transmucosal Drug Delivery Pipeline Report 2024 - Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

November 12, 2024 | finance.yahoo.com

How A.I. Is Disrupting Pharma: The High-Stakes Race to Revolutionize Drug Discovery

November 12, 2024 | observer.com

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

November 7, 2024 | markets.businessinsider.com

EyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy Rating

November 7, 2024 | markets.businessinsider.com

Indian stocks rally over Trump's win; Sensex jumps 901 points

November 6, 2024 | malaysiasun.com

US election: Treasuries slip on election day as volatility hits one-year high

November 6, 2024 | moneycontrol.com

Daily Voice: This fund manager is strategically accumulating positions in healthcare, consumer staples in recent market pullback

November 6, 2024 | moneycontrol.com

US Elections| Why outcome does not matter in the long-run; market strategist makes a $19-million point

November 5, 2024 | moneycontrol.com

How to Talk About Oysters Like You Know What You're Talking About

October 31, 2024 | foodandwine.com

EyePoint Pharma Prices Public Offering Of About 12.73 Mln Shares At $11.00/shr

October 30, 2024 | markets.businessinsider.com

Scotiabank Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

October 29, 2024 | markets.businessinsider.com

EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu

October 29, 2024 | marketwatch.com

Positive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy Rating

October 26, 2024 | markets.businessinsider.com

Positive Outlook for EyePoint Pharmaceuticals Amid Promising Phase 3 Trials for Duravyu

October 25, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OYST, IOVA, ADPT, and NVAX Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.47 +0.33 (+3.25%)

Closing price 04:00 PM Eastern

Extended Trading

$10.44 -0.03 (-0.29%)

As of 07:39 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Iovance Biotherapeutics NASDAQ:IOVA

$2.04 +0.02 (+0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 0.00 (0.00%)

As of 07:54 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Novavax NASDAQ:NVAX

$6.30 -0.19 (-2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$6.28 -0.01 (-0.24%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Oyster Point Pharma NASDAQ:OYST

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time